The impact of comorbid cannabis and methamphetamine use on mental health among regular ecstasy users

Addictive Behaviors

Volumn 37, Issue 9, 2012, Pages 1058-1062

  Scott, Laura A ^a   Roxburgh, Amanda ^a   Bruno, Raimondo ^b   Matthews, Allison ^b   Burns, Lucy ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Cannabis; Ecstasy; K10; Methamphetamine; Psychological distress

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABIS; METHAMPHETAMINE;

ADULT; ANXIETY; ARTICLE; CANNABIS ADDICTION; COMORBIDITY; DEPRESSION; DISTRESS SYNDROME; DRUG USE; HUMAN; KESSLER PSYCHOLOGICAL DISTRESS SCALE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH; METHAMPHETAMINE DEPENDENCE; PARANOIA; RATING SCALE; RISK ASSESSMENT; SELF REPORT;

ADULT; AGED; AMPHETAMINE-RELATED DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HUMANS; MALE; MARIJUANA ABUSE; MENTAL HEALTH; METHAMPHETAMINE; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SELF REPORT; STRESS, PSYCHOLOGICAL; YOUNG ADULT;

EID: 84862699041     PISSN: 03064603     EISSN: 18736327     Source Type: Journal    
DOI: 10.1016/j.addbeh.2012.04.012     Document Type: Article

References (33)

1. Australian Institute of Health and Welfare 2010 National drug strategy household survey report 2011, AIHW, Canberra.
2. Bartley M. Unemployment and ill health: Understanding the relationship. Journal of Epidemiology and Community Health 1994, 48(4):333-337.
3. Bedi G., Van Dam N., Redman J. Ecstasy (MDMA) and high prevalence psychiatric symptomatology: Somatic anxiety symptoms are associated with polydrug, not ecstasy, use. Journal of Psychopharmacology 2010, 24(2):233-240.
4. Bijl R.V., van Zessen G., Ravelli A., de Rijk C., Langendoen Y. The Netherlands Mental Health Survey and Incidence Study (NEMESIS): Objectives and design. Social Psychiatry and Psychiatric Epidemiology 1998, 33(12):581-586.
5. Bleeker A., Silins E., Dillon P., Simpson M., Copeland J., Hickey K. The feasibility of peer-led interventions to deliver health information to ecstasy and related drug users 2009, National Drug and Alcohol Research Centre, University of New South Wales, Sydney.
6. Crippa J.A., Zuardi A.W., Martín-Santos R., Bhattacharyya S., Atakan Z., McGuire P., et al. Cannabis and anxiety: A critical review of the evidence. Human Psychopharmacology: Clinical and Experimental 2009, 24(7):515-523.
7. Darke S., Kaye S., McKetin R., Doflou J. Major physical and psychological harms of methamphetamine use. Drug and Alcohol Review 2008, 27:253-262.
8. Daumann J., Hensen G., Thimm B., Rezk M., Till B., Gouzoulis-Mayfrank E. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: Further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacol 2004, 173(3-4):398-404.
9. Daumann J., Pelz S., Becker S., Tuchtenhagen F., Gouzoulis-Mayfrank E. Psychological profile of abstinent recreational ecstasy (MDMA) users and significance of concomitant cannabis use. Human Psychopharmacology: Clinical and Experimental 2001, 16(8):627-633.
10. Degenhardt L., Roxburgh A., Dunn M., Campbell G., Bruno R., Kinner S., et al. The epidemiology of ecstasy use and harms in Australia. Neuropsychobiology 2009, 60(3-4):176-187.
11. Fukuda Y., Hiyoshi A. Influences of income and employment on psychological distress and depression treatment in Japanese adults 2011, Environ Health, Prev Med, 1-8.
12. Furukawa T.A., Kessler R.C., Slade T., Andrews G. The performance of the K6 and K10 screening scales for psychological distress in the Australian national survey of mental health and well-being. Psychological Medicine 2003, 33:357-362.
13. George J., Kinner S.A., Bruno R., Degenhardt L., Dunn M. Contextualising psychological distress among regular ecstasy users: The importance of sociodemographic factors and patterns of drug use. Drug and Alcohol Review 2010, 29(3):243-249.
14. Gouzoulis-Mayfrank E., Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: A brief overview. Journal of Psychopharmacology 2006, 20(2):188-193.
15. Hall W., Degenhardt L. Adverse health effects of non-medical cannabis use. The Lancet 2009, 374(9698):1383-1391.
16. Kessler R.C., Andrews G., Colpe L.J., Hiripi E., Mroczek D.K., Normand S.-L.T., et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychological Medicine 2002, 32:959-976.
17. King M., Semlyen J., See Tai S., Killaspy H., Osborn D., Popelyuk D.M., et al. A systematic review of mental disorder, suicide, and deliberate self harm in lesbian, gay and bisexual people. BMC Psychiatry 2008, 8:70-87.
18. Lamers C.T.J., Bechara A., Rizzo M., Ramaekers J.G. Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls. Journal of Psychopharmacology 2006, 20(2):302-311.
19. Lubman D.I., Baker A. Cannabis and mental health - Management in primary care. Australian Family Physician 2010, 39(8):554-557.
20. MacInnes N., Handley S.L., Harding G.F.A. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. Journal of Psychopharmacology 2001, 15(3):181-186.
21. Matthews A.J., Bruno R. An investigation of factors associated with depressive symptoms among a sample of regular ecstasy consumers. Neuropsychobiology 2010, 61(4):215-222.
22. McCardle K., Luebbers S., Carter J.D., Croft R.J., Stough C. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacol 2004, 173(3):434-439.
23. McKetin R., Hickey K., Devlin K., Lawrence K. The risk of psychotic symptoms associated with recreational methamphetamine use. Drug and Alcohol Review 2010, 29(4):358-363.
24. McKetin R., Lubman D.I., Lee N.M., Ross J.E., Slade T. Major depression among methamphetamine users entering drug treatment programs. The Medical Journal of Australia 2011, 195(3):S51-S55.
25. Milani R.M., Parrott A.C., Schifano F., Turner J.J.D. Pattern of cannabis use in ecstasy polydrug users: Moderate cannabis use may compensate for self-rated aggression and somatic symptoms. Human Psychopharmacology: Clinical and Experimental 2005, 20(4):249-261.
26. Minozzi S., Davoli M., Bargagli A.M., Amato L., Vecchi S., Perucci C.A. An overview of systematic reviews on cannabis and psychosis: Discussing apparently conflicting results. Drug and Alcohol Review 2010, 29(3):304-317.
27. Parrott A.C., Buchanan T., Scholey A.B., Heffernan T., Ling J., Rodgers J. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Human Psychopharmacology: Clinical and Experimental 2002, 17(6):309-312.
28. Scott R., Hides L., Allen J., Burke R., Lubman D. Depressive and anxiety symptomatology in ecstasy users: The relative contribution of genes, trauma, life stress and drug use. Psychopharmacol 2010, 209(1):25-36.
29. Sindicich N., Burns L. Australian trends in ecstasy and related drug markets 2009: Findings from the Ecstasy and Related Drugs Reporting System (EDRS) 2010, National Drug and Alcohol Research Centre, University of New South Wales, Sydney.
30. Sindicich N., Burns L. Australian trends in ecstasy and related drug markets 2010. Findings from the Ecstasy and Related Drugs Reporting System (EDRS) 2011, National Drug and Alcohol Research Centre, University of New South Wales, Sydney.
31. Slade T., Grove R., Burgess P. Kessler Psychological Distress Scale: Normative data from the 2007 Australian National Survey of Mental Health and Wellbeing. The Australian and New Zealand Journal of Psychiatry 2011, 45:308-316.
32. Topp L., Barker B., Degenhardt L. The external validity of results derived from ecstasy users recruited using purposive sampling strategies. Drug and Alcohol Dependence 2004, 73(1):33-40.
33. Topp L., Breen C., Kaye S., Darke S. Adapting the Illicit Drug Reporting System (IDRS) methodology to examine the feasibility of monitoring trends in party drug markets. Drug and Alcohol Dependence 2004, 73(2):189-197.